Standard Methotrexate Dosing Basics
Methotrexate dosing varies by condition—typically low weekly doses (7.5–25 mg) for rheumatoid arthritis (RA) or psoriasis, higher for cancer (up to 10–12 g/m² weekly or more for acute lymphoblastic leukemia). Guidelines from the American College of Rheumatology (ACR) and FDA labels emphasize body surface area (BSA) for high-dose regimens and renal function monitoring for all.[1][2]
How Age Affects Dosage in Older Adults
Age over 65 prompts lower starting doses due to declining kidney function (glomerular filtration rate drops ~1 mL/min/year after 40), raising toxicity risk. ACR recommends starting RA patients ≥65 at 7.5–10 mg/week (vs. 15 mg/week in younger adults), titrating slowly with creatinine clearance checks. High-dose cancer regimens cap at 75–80% of standard if CrCl <60 mL/min.[1][3]
Renal Adjustments Driving Age-Based Changes
Age correlates with reduced CrCl, the key adjuster:
- CrCl >60 mL/min: Full dose.
- CrCl 30–60 mL/min: 50–75% dose (e.g., RA max 15 mg/week).
- CrCl 10–30 mL/min: 25–50% or avoid oral/low-dose.
Cockcroft-Gault formula estimates CrCl using age, weight, and serum creatinine—older patients often need 25–50% reductions.[2][4]
Dosing in Pediatrics vs. Adults
Children receive higher mg/m² doses for cancer (e.g., 3–5 g/m² IV for leukemia) due to faster clearance, but weight-based caps prevent overdose. Juvenile idiopathic arthritis starts at 10–15 mg/m²/week (max 25 mg flat). Age alone isn't the driver; BSA and growth-adjusted clearance are.[5]
Risks of Overdosing in Elderly Patients
Older adults face 2–5x higher myelosuppression, hepatotoxicity, and GI issues—hospitalizations rise with doses >15 mg/week if CrCl <50. Monthly blood tests and folate supplementation are standard; discontinue if CrCl <30 mL/min long-term.[1][3]
Monitoring and Alternatives for Age-Related Concerns
Check CBC, liver enzymes, and CrCl before each dose escalation. If adjustments fail, switch to biologics (e.g., adalimumab) or leflunomide. No specific age cutoffs in FDA labels, but geriatric data shows 30–50% higher adverse events.[2][6]
[1]: American College of Rheumatology. "2021 RA Treatment Guidelines." rheumatology.org
[2]: FDA. "Methotrexate Label." accessdata.fda.gov (updated 2023)
[3]: UpToDate. "Methotrexate Drug Information." uptodate.com
[4]: Cockcroft DW, Gault MH. Nephron. 1976;16(1):31-41. doi:10.1159/000180580
[5]: Children's Oncology Group. "ALL Protocols." childrensoncologygroup.org
[6]: British Society for Rheumatology. "Methotrexate Guidelines." rheumatology.org.uk